SCHEMBL27148399

SCHEMBL27148399

CCOc1cc2ncnc(Nc3cc(Br)ccc3OC)c2cc1OC1CCNCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.59
▸ KDR P35968 12/20 0.59
▸ FGFR1 P11362 10/20 0.59
▸ FLT1 P17948 10/20 0.59
▸ FLT4 P35916 9/20 0.59
▸ FBP1 P09467 1/20 0.52
▸ ERBB2 P04626 2/20 0.52
▸ ERBB4 Q15303 2/20 0.52
▸ RET P07949 2/20 0.51
▸ KIF5B P33176 2/20 0.51
▸ EPHA2 P29317 5/20 0.51
▸ PDGFRB P09619 2/20 0.49
▸ TEK Q02763 2/20 0.49
▸ EPHB4 P54760 2/20 0.49
▸ BMPR1B O00238 1/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ CIT O14578 1/20 0.49
▸ GAK O14976 1/20 0.49
▸ EPHB6 O15197 1/20 0.49
▸ RIPK2 O43353 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30820454 1.00 EGFR (0.59) EGFRKDRFGFR1FLT1FLT4
SCHEMBL29168736 0.93 EGFR (0.61) EGFRKDRFGFR1FLT1FLT4
SCHEMBL30820521 0.93 EGFR (0.61) EGFRKDRFGFR1FLT1FLT4
SCHEMBL30030964 0.86 EGFR (0.52) EGFRKDRFGFR1FLT1FLT4
SCHEMBL27154368 0.85 EGFR (0.60) EGFRERBB2RETEPHB4RIPK2
SCHEMBL27136126 0.84 EGFR (0.58) EGFRKDRFGFR1FLT1FLT4
SCHEMBL4508831 0.81 EGFR (0.74) EGFRKDRFBP1ERBB2ERBB4
SCHEMBL30822092 0.81 EGFR (0.56) EGFRKDRERBB2RETEPHA2
SCHEMBL27136650 0.81 EGFR (0.56) EGFRKDRERBB2RETEPHA2
Hydrochloric Acid SCHEMBL4077165 0.81 EGFR (0.74) EGFRKDRFBP1ERBB2ERBB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC. (KR) 2024-07-25 — — US disclosed
CN-117693505-A Heteroaryl derivative compounds and uses thereof 沃若诺伊公司 2024-03-12 — — CN disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 — — EP disclosed
EP-4328222-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-02-28 — — EP disclosed
WO-2022225238-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 보로노이 주식회사 2022-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246940-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF ERBB2, EGFR, ERBB3 EGFR 2/4885KDR 24/4885FGFR1 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback